Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
Patients admitted within 4 hours of the onset of chest pain suggestive of acute myocardial infarction were randomised to either intravenous anisoylated plasminogen streptokinase activator complex (APSAC) 30U or heparin 5000U (44 vs 38 patients). Angiograms were obtained between days 10 and 15 after admission. Late coronary patency was recorded in a significantly higher proportion of patients in the APSAC group (79% vs 42%, p less than 0.001). The global ejection fraction showed only a favourable trend: 55.3 +/- 12% for the APSAC group vs 54.1 +/- 13.1% for the heparin group; this trend was only observed in the inferior infarction group. Regional wall motion analysis did not show any significant difference between treatment groups.
Taeymans
Y
Y
Department of Cardiology, University Hospital VUB, Brussels.
Materne
P
P
D016255:Anistreplase; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000187:drug effects*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy*; D010958:Plasminogen / Q000627:therapeutic use*; D011897:Random Allocation; D013300:Streptokinase / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D016255:Anistreplase; D010958:Plasminogen; D006493:Heparin; D013300:Streptokinase